Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED
  5. VGI Health Technology Limited
  6. News
  7. Summary
    VTL   AU0000152597

VGI HEALTH TECHNOLOGY LIMITED

(VTL)
End-of-day quote NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED  -  2022-06-28
0.0300 AUD   -70.00%
10/13VGI Health Technology Limited R & D Facility Agreement with Fundsquire Pty Ltd
AW
10/13Vgi Health Technology Limited (nsx : VTL) R & D Facility Agreement with Fundsquire Pty Ltd
AQ
10/04VGI Health Technology Limited NAFLD/NASH Phase II Clinical Study
AW
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH Phase II Clinical Study

10/04/2022 | 05:58pm EST

Sydney, Australia, Oct 5, 2022 - (ABN Newswire) - VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).

Dosing of Invictus' NAFLD/NASH drug candidate IVB001 has commenced for 1 patient at The Gallipoli Medical Research Foundation in Queensland and 3 patients at The John Hunter Hospital in New South Wales. A total of 80 patients will be recruited and dosed for this study which is a randomised, double-blind, placebo-controlled Phase II clinical study on NAFLD/NASH to analyse the efficacy and safety of IVB001, a drug candidate based on the non-invasive and direct delivery of tocotrienols using Invictus' patented transmucosal delivery platform.

Dr David Kingston, the Chief Scientific Officer of VTL, said "Unlike many other Phase II clinical studies, the present study is based on efficacy signals derived from clinical studies on orally administered tocotrienols rather than animal studies and we have seen some promising results in NAFLD/NASH patients who have been administered a dietary supplement which is closely aligned to the drug candidate IVB001. This study is showing a lot of promise and we hope to be able to address the great unmet need presented by NAFLD/NASH."


<b>About VGI Health Technology Limited:</b>

VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

<b>Contact:</b>

Glenn Tong
CEO and Managing Director
Ph: +61 (0) 412 193 350

Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431

Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

Copyright (C) 2022 ABN Newswire. All rights reserved., source Press Releases English

All news about VGI HEALTH TECHNOLOGY LIMITED
10/13VGI Health Technology Limited R & D Facility Agreement with Fundsquire Pty Ltd
AW
10/13Vgi Health Technology Limited (nsx : VTL) R & D Facility Agreement with Fundsquire Pty Ltd
AQ
10/04VGI Health Technology Limited NAFLD/NASH Phase II Clinical Study
AW
10/04Vgi Health Technology Limited (nsx : VTL) NAFLD/NASH Phase II Clinical Study
AQ
09/25VGI Health Technology Limited Receives Ethics Approval for US Clinical Study
AW
09/13VGI Health Technology Limited NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient
AW
09/13Vgi Health Technology Limited (nsx : VTL) NAFLD/NASH PhaseII Clinical Study Recruits 1st P..
AQ
08/10VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt
CI
08/09Vgi Health Technology : Annual Report for the year ended 30 June 2022
PU
08/09VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30,..
CI
More news
Financials
Sales 2022 0,01  0,01  0,01 
Net income 2022 -7,87 M -5,29 M -5,29 M
Net Debt 2022 1,76 M 1,18 M 1,18 M
P/E ratio 2022 -0,53x
Yield 2022 -
Capitalization 4,15 M 2,79 M 2,79 M
EV / Sales 2021 -
EV / Sales 2022 435 205 817x
Nbr of Employees -
Free-Float 0,87%
Chart VGI HEALTH TECHNOLOGY LIMITED
Duration : Period :
VGI Health Technology Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Glenn Tong CEO, Managing Director & Executive Director
Ian Forbes Chief Financial Officer
Louis James Panaccio Independent Non-Executive Chairman
David Kingston Chief Scientific Officer
Jiayi Yu Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
VGI HEALTH TECHNOLOGY LIMITED-88.00%3
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.21.36%81 852
BIONTECH SE-35.33%41 250
WUXI APPTEC CO., LTD.-34.04%32 901
GENMAB A/S24.18%30 145